Login to Your Account



PHASE II FAILED, BUT . . .

Culture club: FDA gets aboard with Arikayce in Insmed's NTM bid

By Randy Osborne
Staff Writer

Wednesday, June 18, 2014
Insmed Inc.'s eventful ride with Arikayce (inhaled liposomal amikacin) took an upswing with word from the FDA that the compound has achieved breakthrough designation in nontuberculous mycobacterial (NTM) lung disease, despite missing its primary endpoint in a phase II trial in that indication.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription